BRMS1L

Across TCGA pan-cancer cohorts, BRMS1L mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BRMS1L’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where BRMS1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BRMS1L is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, HNSC, and LSCC are the cancer types where BRMS1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRMS1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−0.681	<.001	9	view →
HNSC	All	All	−0.139	.009	4	view →
LSCC	Male	All	+0.120	.001	4	view →
LUAD	All	All	+0.087	.004	4	view →
OV	All	All	−0.446	.022	2	view →
CCRCC	All	II,III,IV	−0.094	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BRMS1L–PDAC

Open the PDAC breakdown →